Hessekiel Jeffrey
Known title: EVP and General CounselCIK: 0001599803
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Exelixis Shares Rise on CABOMETYX Revenue. Exelixis stock has moved higher following reports of strong revenue from its drug CABOMETYX. This performance is relevant as it demonstrates the commercial strength of the company's primary product. The FDA also expanded the label for Merck's Welireg, a competitor in the kidney cancer space, which adds context to the market environment.
Transaction History
| CYTK | ▲ Buy | Grant | 20,646 | $0 | 3/15/2026 | View on chart |
| CYTK | ▲ Buy | Grant | 87,297 | $0 | 11/14/2025 | View on chart |
| EXEL | ▼ Sell | Tax Withholding | 34,035 | $1.5M | 5/15/2025 | View on chart |
| EXEL | ▼ Sell | Open Market | 25,000 | $1.2M | 5/15/2025 | View on chart |
| EXEL | ▲ Buy | Grant | 154,070 | $0 | 3/31/2025 | View on chart |
| EXEL | ▲ Buy | Grant | 52,192 | $0 | 2/26/2025 | View on chart |
| EXEL | ▼ Sell | Tax Withholding | 18,134 | $635K | 2/15/2025 | View on chart |
| EXEL | ▲ Buy | Grant | 118,780 | $0 | 1/16/2025 | View on chart |
| EXEL | ▼ Sell | Tax Withholding | 26,289 | $980K | 1/16/2025 | View on chart |
| EXEL | ▼ Sell | Open Market | 60,000 | $2.2M | 11/29/2024 | View on chart |
| EXEL | ▼ Sell | Gift | 15,000 | $0 | 11/29/2024 | View on chart |
| EXEL | ▲ Buy | Option Exercise | 129,314 | $2.4M | 11/27/2024 | View on chart |
| EXEL | ▼ Sell | Tax Withholding | 98,908 | $3.6M | 11/27/2024 | View on chart |
| EXEL | ▼ Sell | Tax Withholding | 14,672 | $514K | 11/15/2024 | View on chart |
| EXEL | ▼ Sell | Open Market | 50,000 | $1.7M | 11/1/2024 | View on chart |
| EXEL | ▼ Sell | Open Market | 25,000 | $710K | 10/28/2024 | View on chart |
| EXEL | ▼ Sell | Open Market | 25,000 | $660K | 9/23/2024 | View on chart |
| EXEL | ▲ Buy | Option Exercise | 20,000 | $488K | 8/26/2024 | View on chart |
| EXEL | ▼ Sell | Open Market | 20,000 | $516K | 8/26/2024 | View on chart |
| EXEL | ▲ Buy | Option Exercise | 80,000 | $2.0M | 8/7/2024 | View on chart |
| EXEL | ▼ Sell | Open Market | 80,000 | $2.1M | 8/7/2024 | View on chart |
| EXEL | ▼ Sell | Tax Withholding | 7,240 | $152K | 5/15/2024 | View on chart |
| EXEL | ▼ Sell | Tax Withholding | 8,600 | $181K | 5/15/2024 | View on chart |
| EXEL | ▼ Sell | Tax Withholding | 10,101 | $212K | 5/15/2024 | View on chart |
| EXEL | ▲ Buy | Grant | 63,350 | $0 | 2/23/2024 | View on chart |
| EXEL | ▲ Buy | Grant | 71,418 | $0 | 1/11/2024 | View on chart |
| EXEL | ▼ Sell | Tax Withholding | 13,061 | $299K | 1/11/2024 | View on chart |
| EXEL | ▼ Sell | Open Market | 25,000 | $575K | 12/13/2023 | View on chart |
| EXEL | ▼ Sell | Open Market | 25,000 | $552K | 12/4/2023 | View on chart |
| EXEL | ▼ Sell | Open Market | 25,000 | $550K | 11/30/2023 | View on chart |
| EXEL | ▲ Buy | Grant | 57,900 | $0 | 9/6/2023 | View on chart |
| EXEL | ▼ Sell | Tax Withholding | 14,354 | $320K | 9/6/2023 | View on chart |
| EXEL | ▼ Sell | Tax Withholding | 7,177 | $154K | 8/15/2023 | View on chart |
| EXEL | ▲ Buy | Option Exercise | 55,710 | $821K | 8/1/2023 | View on chart |
| EXEL | ▼ Sell | Open Market | 55,710 | $1.1M | 8/1/2023 | View on chart |
| EXEL | ▼ Sell | Tax Withholding | 4,940 | $95K | 5/15/2023 | View on chart |
| EXEL | ▼ Sell | Tax Withholding | 7,027 | $135K | 5/15/2023 | View on chart |
| EXEL | ▼ Sell | Open Market | 38,930 | $779K | 4/5/2023 | View on chart |
| EXEL | ▲ Buy | Option Exercise | 13,930 | $205K | 4/5/2023 | View on chart |
| EXEL | ▲ Buy | Grant | 79,719 | $0 | 4/3/2023 | View on chart |
| EXEL | ▲ Buy | Option Exercise | 27,860 | $411K | 3/1/2023 | View on chart |
| EXEL | ▼ Sell | Open Market | 77,860 | $1.3M | 3/1/2023 | View on chart |
| EXEL | ▼ Sell | Tax Withholding | 1,929 | $35K | 2/15/2023 | View on chart |
| EXEL | ▼ Sell | Tax Withholding | 7,177 | $120K | 11/15/2022 | View on chart |
| EXEL | ▲ Buy | Grant | 28,950 | $0 | 8/3/2022 | View on chart |
| EXEL | ▼ Sell | Tax Withholding | 7,177 | $154K | 8/3/2022 | View on chart |
| EXEL | ▼ Sell | Open Market | 18,000 | $361K | 5/16/2022 | View on chart |
| EXEL | ▼ Sell | Tax Withholding | 5,349 | $107K | 5/15/2022 | View on chart |
| EXEL | ▼ Sell | Open Market | 13,283 | $292K | 3/29/2022 | View on chart |
| EXEL | ▼ Sell | Open Market | 4,717 | $104K | 3/28/2022 | View on chart |
| EXEL | ▲ Buy | Grant | 67,875 | $0 | 3/4/2022 | View on chart |
| EXEL | ▼ Sell | Open Market | 18,000 | $360K | 2/24/2022 | View on chart |
| EXEL | ▼ Sell | Tax Withholding | 1,017 | $19K | 2/15/2022 | View on chart |
| EXEL | ▼ Sell | Tax Withholding | 11,209 | $208K | 2/15/2022 | View on chart |
| EXEL | ▲ Buy | Grant | 9,994 | $0 | 12/15/2021 | View on chart |
| EXEL | ▼ Sell | Tax Withholding | 2,621 | $45K | 12/15/2021 | View on chart |
| EXEL | ▼ Sell | Tax Withholding | 6,557 | $119K | 11/15/2021 | View on chart |
| EXEL | ▼ Sell | Tax Withholding | 1,311 | $24K | 11/15/2021 | View on chart |
| EXEL | ▼ Sell | Tax Withholding | 46,743 | $846K | 11/15/2021 | View on chart |
| EXEL | ▼ Sell | Open Market | 5,117 | $113K | 11/1/2021 | View on chart |
| EXEL | ▼ Sell | Open Market | 12,883 | $284K | 10/15/2021 | View on chart |
| EXEL | ▲ Buy | Grant | 28,950 | $0 | 9/30/2021 | View on chart |
| EXEL | ▼ Sell | Tax Withholding | 7,593 | $157K | 9/30/2021 | View on chart |
| EXEL | ▼ Sell | Open Market | 18,000 | $457K | 5/17/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Cytokinetics Launches ASPEN-HCM Real-World Study
Cytokinetics has initiated the ASPEN-HCM study to evaluate MYQORZO in real-world patients with symptomatic obstructive hypertrophic cardiomyopathy. The company also announced four upcoming presentations at the HFSA Annual Scientific Meeting 2026. These clinical updates provide new data points for investors, while the stock currently trades near its 52-week low.
Cytokinetics Launches ASPEN-HCM Real-World Study. Cytokinetics has initiated the ASPEN-HCM study to evaluate MYQORZO in real-world patients with symptomatic obstructive hypertrophic cardiomyopathy. The company also announced four upcoming presentations at the HFSA Annual Scientific Meeting 2026. These clinical updates provide new data points for investors, while the stock currently trades near its 52-week low.